Navigation Links
Sangamo BioSciences Reports Third Quarter 2013 Financial Results
Date:10/23/2013

onal control of the virus at or below the limit of quantification (LOQ) in CCR5 delta-32 heterozygote HIV-infected subjects.  The abstract was selected as a "late-breaker" presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  The data demonstrate that viral load (VL) became undetectable during a treatment interruption (TI) from antiretroviral therapy (ART) in three of seven evaluable CCR5 delta-32 heterozygote HIV-infected subjects, including two of six subjects that had completed TI in the ongoing SB-728-902 Cohort 5 study and an additional subject from an earlier Phase 1 clinical trial of SB-728-T.  In one SB-728-902 Cohort 5 subject, VL remained undetectable for seven weeks, to the last measurement taken prior to the presentation.  Reduction in VL from peak during TI showed a statistically significant correlation (p=0.015) with estimated numbers of engrafted ZFN modified cells (SB-728-T) in which both copies of the CCR5 gene had been disrupted (biallelic modification), in line with previously presented data from this program. Data were also presented demonstrating depletion of the HIV viral reservoir in SB-728-T treated subjects in cohorts 1-3 of the SB-728-902 study.
  • Acquisition of Ceregene, Inc. On October 1, Sangamo completed the acquisition of Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies. Under the terms of the agreement, Sangamo issued 100,000 shares of Sangamo's common stock to the stockholders of Ceregene and also agreed to make certain contingent earnout payments based upon revenues generated from the license or sales transaction of certain existing products of Ceregene. Sangamo  received over 120 issued, pending or in-licensed patents, access to GMP master cell banks, materials and manufacturing know-how, as well as a database of preclinical efficacy and toxicology studies and other documentation sup
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
    2. Sangamo BioSciences Proposes Public Offering Of Common Stock
    3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
    4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
    5. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
    6. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
    7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
    8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
    9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
    10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
    11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... “Preparative & Process Chromatography Market ... (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, ... Forecasts to 2019” provides a detailed overview of ... trends, and strategies impacting the preparative and process ... of the revenue and share analysis. , ...
    (Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ... The only negative is the housing market remaining soft. ...
    (Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
    (Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
    Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
    ... DIEGO, Sept. 2 Results from studies related to Optimer ... will be presented at the 49th Annual Interscience Conference ... Center in San Francisco on September 12-15, 2009. , , ... , , Fidaxomicin abstracts and speakers include:, ...
    ... , SOUTH SAN FRANCISCO, Calif., Sept. 1 ... first commercial sales of a new 20 microgram per milliliter ... Heart Association Class III and IV pulmonary arterial hypertension (PAH). ... in half the volume, which is expected to reduce inhalation ...
    ... , , ST. LOUIS, Sept. 1 ... at the following investor conferences in September: , , Thomas ... at The Four Seasons Hotel in Boston, MA. , , ... at the Grand Hyatt Hotel in New York, NY. , , ...
    Cached Biology Technology:Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 3Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 2Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 3Express Scripts to Present at Investor Conferences 2
    (Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
    (Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
    (Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
    Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
    ... held Aug. 24-27 at the National Center for Atmospheric Research ... pay tribute to Steve Schneider,s contributions to climate science and ... Steve Schneider was a leader in science communication and an ... death on July 19, 2010, he was the Melvin and ...
    ... announced the publication of several commentaries in the scientific journal ... many embryos it is safe and proper to place in a ... dilemma faced by all patients anxiously caught between no pregnancies at ... difficult place it is often all too easy to think that ...
    ... 26, 2011 The world,s largest scientific society picked the perfect ... the American Chemical Society (ACS) Office of Public Affairs invites your ... venue for the theme The Chemistry of Air, Space and ... in and near Denver ranging from hot air balloon rides, ...
    Cached Biology News:IVF treatment and multiple births: Free-market patient rights versus government regulation 2IVF treatment and multiple births: Free-market patient rights versus government regulation 3News media registration for American Chemical Society National Meeting Denver, Aug. 28-Sept. 1, 2011 2
    ...
    Alexa Fluor 647 anti-mouse Qa-2...
    Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
    normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
    Biology Products: